Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted by positive late-stage melanoma trial results. Pfizer and BioNTech, also vaccine peers, saw smaller gains. The key question is whether Moderna's stock can sustain its gains after index funds complete their purchases, with future oncology data expected to influence its valuation.
As of Oct 09, 2026 23:02 WIB, Moderna (MRNA) surged 8.19% to USD 213.13 on Pluang, outpacing Pfizer's modest 0.83% rise to USD 28.05, which remains close to its 52-week high of USD 29.02. BioNTech (BNTX) also climbed 3.49% to USD 95.27 but still trades well below its 52-week peak of USD 119.34. Moderna's sharp gain contrasts with Pfizer's longer typical hold time of 158 days versus Moderna's 59 days, highlighting differing investor engagement levels amid the recent NASDAQ 100 inclusion news.
Novavax shares surged 16%, leading a biotech sector rally alongside Moderna's 11% gain and Merck's 3% rise. The spike occurred without any new company-specific announcements, driven by a broad sector-wide bid in vaccine and biotech stocks. Novavax's ...
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
